A 54-year-old woman presented with slow-growing cervical lymph nodes, weight loss and disseminated skin rash in February 2006. Biopsies from skin and cervical node revealed angioimmnunoblastic T-cell lymphoma (AILT), stage IVB. She received chemotherapy with cyclophospamide, doxorubicin, vincristine and prednisone, with a transient improvement of the skin rash and cervical nodes, followed by progression after three cycles. Second line with etoposide, methylprednisolone, cytarabine and cisplatin was tried, and again a short response followed by a rapid progression was observed, together with an important decrease in performance status and pancytopenia. She then started weekly oral methotrexate (20 mg) and daily prednisone (15 mg). After 3 months on treatment with disease stabilization, progression in skin, lymph nodes and bone marrow was observed. Her clinical condition was poor, developing deep venous thrombosis, pancytopenia and fever. At this point, fourth-line chemotherapy or alentuzumab was felt not possible, and therapy with the monoclonal anti-vascular endothelial growth factor (VEGF) antibody bevacizumab was started in September 2006 at a dose of 10 mg/kg every 14 days. After three doses, blood counts rose to normal values and her general condition improved. She maintained low-dose prednisone (5 mg daily) and then switched to 30 mg daily for 5 days after every bevacizumab administration. Quality of life and tolerance were excellent, with only arterial hypertension grade 3 requiring combination antihypertensive agents as relevant toxicity. A complete response with total disappearance of enlarged lymph nodes and bone marrow infiltration, assessed by bone marrow biopsy and computed tomography scan, was observed after 3 months of therapy, lasting for 10 months. However, in July 2007, a new disseminated relapse occurred and the patient died in a few weeks.